米氮平治疗抑郁症的临床疗效

被引:29
作者
熊鹏
宣熙
王继才
机构
[1] 昆明医学院第一附属医院精神科
关键词
抑郁症; 米氮平; 丙咪嗪;
D O I
暂无
中图分类号
R749.4 [情感性精神病];
学科分类号
摘要
目的 评价米氮平治疗抑郁症的临床疗效和安全性。方法 对符合CCMD 3抑郁症诊断标准的 5 3例抑郁症患者进行米氮平和丙咪嗪的对照研究 ,其中米氮平组 30例 (15~ 4 5mg/d) ,丙咪嗪组 2 3例 (10 0~ 2 0 0mg/d) ,共治疗 6周。采用汉密顿抑郁量表HAMD ,汉密顿焦虑量表HAMA ,临床总体评定量表CGI评定临床疗效 ,副反应量表TESS评定不良反应。结果 经 6w治疗后 ,米氮平组治疗总有效率为 87% ,显效率为 6 9% ,丙咪嗪组分别为 86 %和 6 7% ,两组相比较 ,差异无显著性 (P >0 0 5 )。米氮平组治疗第 1周就起效。两组的HAMD ,AHMA评分治疗前后相比较差异有高度显著性(P <0 0 1) ;两组之间比较差异无显著性 (P >0 0 5 )。米氮平组的不良反应相对于丙咪嗪组少而轻 ,常见的有头昏、口干、胃肠不适等。结论 米氮平治疗抑郁症疗效好 ,起效快 ,不良反应少而轻 ,适合临床应用。
引用
收藏
页码:93 / 95+116 +116
页数:4
相关论文
共 13 条
  • [1] Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Stahl S,Zivkov M,Reimitz PE,et al. Acta Psychiatrica Scandinavica . 1997
  • [2] The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. De Boer T. International Clinical Psychopharmacology . 1995
  • [3] Mirtazapinecomparedwithparoxetineinmajordepression. BenkertO,SzegediA,KohnenR. JClinPsychiatry . 2000
  • [4] Mirtazapine: a review of its use in major depression. Holm KJ,Markham A. Drugs . 1999
  • [5] Acute and subchronic effects of mirtazapine (15~30 mg nocte) and mianserin (30~60 mg nocte) on psychomotor and actual driving performance and sleep in healthy, young volunteers. Ramaekers JG,Muntjewerff ND,O Hanlon JF. European Neuropsychopharmacology . 1995
  • [6] Antidepressant treatment of the depressed patient with insomnia. Thase ME. Journal of Clinical Psychiatry . 1999
  • [7] Safety of mirtazapine: a review. Montgomery SA. International Clinical Psychopharmacology . 1995
  • [8] Clinicalefficacyofmirtazapine:areviewofmeta analysesofpooleddata. KasperS. International Clinical Psychopharmacology . 1995
  • [9] Thealphα2 selectivea drenoceptorantagonistOrg3770 (mirtazapine,Remeron)enhancesnoradrenergicandserotonergictransmission. DoBoert,RuitGSF,BerendsenHHG. HumPsychopharmcol . 1995
  • [10] Mirtazapine:efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder.Mirtazapine-Fluoxetine Study Group. Wheatley DP,Van Moffaert M,timmerman L,et al. Journal of Clinical Psychiatry . 1998